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Preparation of Compound 4. To a solution of 5-bromo-benzofuran-2-carboxylic acid ethyl ester (1.115 g, 4. 14 mmol) in dioxane (12 ml) was added 4-methoxyphenylboronic acid (0.691 g, 4.55 mmol) followed by a solution of sodium carbonate (1.45 g) in water (12 ml) and tetrakis(triphenylphosphine)palladium (0.053 g, 0.046 mmol) under argon. The mixture was heated at 95 o C for 4 h. After cooling, 2N HCl was added to pH 2, then the mixture was extracted with ethyl acetate. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness to obtain crude 5-(4-methoxyphenyl)-benzofuran-2-carboxylic acid (1.42 g) . A mixture of crude acid and pyridine hydrochloride (7.4 g, 64 mmol) was heated to [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] o C for 1.5 h. After cooling, 2N HCl was added to pH 1-2, then the mixture was extracted with ethyl acetate. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness to obtain crude 5-(4-hydroxyphenyl)-benzofuran-2-carboxylic acid (1.15 g) . To a solution of the latter in dimethylformamide (20 ml) were added tertbutyldimethylsilyl chloride (1.49 g, 9 .91 mmol) and imidazole (1.22 g, 17 .97 mmol) under argon. The mixture was stirred overnight. After 2N HCl was added to pH 1-2, the mixture was extracted with ether. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness. Purification by flash column (SiO 2 , 98:2 dichloromethane/methanol + 0.25% acetic acid) gave 5-(4-tert-butyldimethylsilyloxyphenyl)-benzofuran-2-carboxylic acid (0.957 g, 63% for 3 steps). To the latter (3.62 g, 9.82 mmol) in tetrahydrofuran (100 ml) was added 1M lithium aluminum hydride in tetrahydrofuran (19.5 ml, 19.5 mmol) at 0-5 o C under argon. The ice bath was removed, and the mixture was stirred for 2 h, cooled to 0-5 o C and sodium sulfate decahydrate (ca. 20 g) was added. The mixture was stirred for 10 minutes, brought to pH 6-7 with 10% aqueous KHSO 4 /Na 2 SO 4, and filtered. 60%) . To this alcohol (0.3 g, 0.81 mmol) and (R)-2-isocyanato-3-phenyl-propionic acid methyl ester (0.18 g, 0.87 mmol) in tetrahydrofuran (10 ml) was added triethylamine (0.24 ml, 1.7 mmol) under argon. The mixture was heated at reflux overnight. The mixture was cooled, brought to pH 2 with 10% aqueous KHSO 4 /Na 2 SO 4 , then extracted with ethyl acetate. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness.
Purification by flash column (SiO 2 , 98:2 toluene/ethyl acetate) gave (R)-2-{5-[4-(tertbutyldimethylsilyloxy)-phenyl]-benzofuran-2-ylmethoxycarbonylamino}-3-phenyl-propionic acid methyl ester (0.38 g, 81%). To the latter (0.38 g, 0.68 mmol) in tetrahydrofuran (4 ml) was added 1.0M tetra-n-butylammonium fluoride in tetrahydrofuran (0.71 ml, 0.71 mmol)
under argon. The mixture was stirred for 1.5 h. 1N HCl was added to pH 1-2, then the mixture was extracted with ether. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness. Purification by flash column (SiO 2 , 75:25 hexane/ethyl acetate) gave (R)-2-[5-(4-hydroxyphenyl)-benzofuran-2-ylmethoxycarbonylamino]-3-phenylpropionic acid methyl ester (0.23 g, 75%), which was dissolved in tetrahydrofuran (4 ml) and water (1 ml) and treated with lithium hydroxide hydrate (0.042 g, 1.0 mmol) for 1 h. Following the addition of 2N HCl to pH 1-2, the mixture was extracted with ethyl acetate. The extract was washed with brine, dried on sodium sulfate and concentrated to dryness. Crystallization from dichloromethane/hexane gave compound 4 (0.2 g, 92% 74, 36.03, 41.06, 51.84, 56.47, 58.51, 58.88, 62.97, 107.08, 111.80, 115.15, 119.82, 119.82, 124.38, 127.28, 127.45, 128.64, 129.31, 131.38, 136.02, 140.79, 153.64, 153.94, 154.39, 155.79, 159.80, 163.01, 170.46, 171.12, 171.95, 173.42, 200.92 .
Synthesis of glutathione related metabolites. Following the procedure of Grillo and
Benet (Grillo and Benet, 2001 ), a 1.8 mg sample of 20 was dissolved in a minimum volume of dimethylsulfoxide (100 µl) and diluted to 22 ml with pH 7.4 phosphate buffer. To this solution was added 0.8 mg of γ-glutamyltranspeptidase (Type II from bovine kidney, Sigma #64756, 26 units/mg) and the reaction was incubated at 37 o C. The reaction was followed by taking periodic aliquots, diluting 1x with acetonitrile and injecting on LC/MS with Method C.
After 2 h, the reaction was complete and the products were isolated by acidifying to pH 2 with 1 N HCl and extracting 3 times (20 ml) with ethyl acetate. The extracts were dried on magnesium sulfate and evaporated. Compound 18 was isolated by preparative HPLC and characterized as described in the results.
In vitro metabolism studies. Microsomes. The preparation and characterization of the rat microsomes used in these studies was similar to previously published methods (Swinney et al., 1994) . Incubation mixtures (0.5 ml) contained compound 1, 2 or 3 (10µM with a maximum of 1% dimethylsulfoxide used as cosolvent), phosphate buffer (100 mM), NADPH
(1 mM), magnesium chloride (5 mM) and microsomal protein (1 mg/ml) and were allowed to react at 37°C for 30 min. Hepatocytes. Rat hepatocytes were isolated based on a 2-step perfusion as previously described (Seglen, 1976) . Briefly, the liver was perfused with Gibco Liver Perfusion Medium (Invitrogen, Carlsbad, CA) for 5 -8 min, followed by Gibco Liver Digest Medium for 6 -10 min. Dog hepatocytes were purchased from In Vitro Technologies (Baltimore, MD). Hepatocytes were plated in 24-well collagen-coated cell culture plates (200,000 cells per well) and maintained in a humidified atmosphere of 5% carbon dioxide at 37 °C. Incubation mixtures (0.5 mL) contained compound 1, 2 or 3 (10µM with a maximum of 1% dimethylsulfoxide used as cosolvent) in Gibco HepatoZYME media supplemented with 5% FBS and 2 mM L-glutamine and were allowed to react for up to 24 h.
In vivo metabolism studies. A total of 5 radiolabelled, in vivo studies were conducted.
Doses for all animal studies were administered as solutions in 100 mM tris[hydroxymethyl]aminomethane (pH 7-9). Bile-duct-cannulated male Han:Wistar rats were obtained from Charles River Laboratories (Hollister, CA). Rats were administered 2 ( 14 Clabeled, 5 mg/kg PO, 132 mCi/mg) and bile was collected for 24 h post-dose. Female beagles and male cynomolgus monkeys used in these studies were equipped with Kissinger Biliary Diversion Devices (Kissinger and Garver EM, 1998) a Sciex API4000 triple quadrupole mass spectrometer. Accurate masses were determined on a Waters API-US qTOF using leucine enkephalin lock mass in negative ion mode.
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Results
The structures of title compounds and important metabolites are shown in Table 1 . Full synthetic details for the preparation of the 14 C labeled versions of the title compounds, 1-3, as well as the hydroxy metabolites, 4-6, are included in the experimental. Since mass spectrometry was used for all structure determinations, Table 1 Table 1 ) is cleaved to yield a 5-phenylbenzofuranylmethyl alcohol and an isocyanate. The alcohol is termed the "left side". It is not observable in negative ion unless a negative stabilizing substituent such as sulfate is present. The isocyanate is termed the "right side" and is always observable in negative ion spectra. A secondary loss of HNCO is often observed from the rightside fragment. For compound 1 the primary and secondary rightside ions are observed at m/z 190 and 147 respectively.
Oxidative metabolism of 1-3; compounds 4-6 and their conjugates. The structures of the metabolites, along with their MS data and whether they were observed in vitro, in vivo and/or synthesized, are shown in Table 1 . Rat liver microsome incubations showed that 1 and 14 C-labelled 1 are converted readily to the mono-oxidized derivatives 4 and 5. The MS/MS-observed rightside ion for compound 4 is the same as that seen for 1. For compound 5, the rightside ion is displaced 16 amu. These identifications were confirmed by When the rightside oxidation is blocked by fluorine in molecule 2, the leftside oxidation to
give 6 is a major pathway. Compound 6 and its sulfate were also identified by their characteristic fragmentation, sulfatase treatment and synthesis. The oxidative metabolism of 1 is complicated by additional sites of oxidation on each ring. Additional leftside oxidation is also seen with compound 2. Compounds 1 and 2 also form dihydrodiol and glutathione adduct metabolites from aromatic oxidative pathways. Several of these were observed as minor metabolites in vivo but were not characterized by isolation; the regiochemistry of these metabolites is not known. Fig. 1 shows the base peak, negative ion electrospray mass (top), UV (middle) and radio (bottom) chromatograms (Method B) for a sample of bile from a dog treated with compound 2. The MS data is convoluted by the presence of the large peak due to bile acid. The UV and radio chromatograms are in remarkable concordance. The oxidative metabolites and their conjugates all elute much earlier than parent compound 2 at this pH on a C18 column.
In addition to compound 6 and its sulfate (labeled 6S), this sample shows large amounts of the glucuronide and sulfate (labeled 6'G and 6'S) of the unknown leftside mono-oxidation regioisomer of 6 and a sulfate (labeled DHS) of a dihydroxy metabolite. The dihydroxy This article has not been copyedited and formatted. The final version may differ from this version. (Davis et al., 2002) . The accurate masses of the molecular ion of 13 and its three key fragments were determined as shown in Table 2 . The data is consistent with a formula of C 31 H 28 F 2 N 3 O 7 S and the losses being C 15 H 11 NO 2 (the leftside), followed by CH 3 SH, followed by CO 2 . This data reveals that the conjugating increment in 13 has the formula C 6 H 10 N 2 O 2 S and is best explained as the Smethylcysteinylglycine conjugate formed by secondary metabolism of a glutathione conjugate (Grillo and Benet, 2001 ); see 
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H=592 which must be the monomer structure B (Fig. 2) . In MS/MS, peak B loses a leftside to give m/z 368, followed by loss of H 2 S to give m/z 334. Peak B disappeared when this reaction was worked up.
The late eluting peaks of Fig. 3 
of bile, the major radioactive components were parent, 8 and 6S. The glutathione derived metabolites 12, 14, 16 and 18 were not observed in rat.
When compound 2 was administered to dogs, 43.8% and 2.5% of the dose was excreted respectively in bile and urine within 24 hr. No urinary metabolites were identified. In the case of bile, the major radioactive components were parent, 8 and 6'S. Compounds 12, 14, 16 and 18 added together constituted 6.1% of the radioactivity observed in bile.
When compound 3 was administered to monkeys, 43.7% and <1% of the dose was excreted respectively in bile and urine within 24 hr. No urinary metabolites were identified. In the case of bile, the major radioactive components were parent, 9 and 19. Compounds 13, 15, 17 and 19 added together constituted 25.7% of the radioactivity observed in bile.
When compound 3 was administered to dogs, >95% and <1% of the dose was excreted respectively in bile and urine within 24 hr. No urinary metabolites were identified. In the case of bile, the major radioactive components were parent, 9 and 19. Compounds 13, 15, 17 and 19 added together constituted 17.9% of the radioactivity observed in bile.
Discussion
The metabolism of compounds 1-3 can be summarized with the scheme shown as The introduction of a second fluorine (compound 3) essentially blocks all aromatic oxidations. The in vivo metabolism of 3 is thus dominated by the conjugation of the carboxylic acid moiety to yield taurine and acyl glucuronide conjugates and most interestingly, a set of glutathione derived metabolites. Benet and his colleagues have characterized this metabolic pathway for clofibric acid (Grillo and Benet, 2001; Shore et al., 1995; Stogniew and Fenselau, 1982) . Clofibric acid metabolites analogous to 12 and 16
were observed in urine of rats treated intravenously with the glutathione conjugate of clofibric acid; but intraperitoneal administration of the free acid yielded only small amounts of the disulfide (Grillo and Benet, 2001 ). probably derived via intermediacy of an acyl-CoA derivative or the acyl glucuronide, 8 Li et al., 2002) . We have not observed the relatively unstable acyl CoA metabolite or the acyl glutathione metabolite in hepatocyte incubations or in vivo, but others are reporting these with careful study . When synthetic 20 is exposed to γ-glutamyltranspeptidase, it is converted to two even-more unstable intermediates. The primary product, labeled A in Fig. 2 undergoes an S,N intramolecular acyl transfer to form product B. Product B is unstable in relation to dimerization. In the in vitro reaction, it is converted to the S-S dimer, 16, or to the N,S-diacyl peptide 18. In vivo, an alternative stabilization of B is found through S-methylation to give 12.
Further oxidation of 12 gives the stable sulfoxide 13.
The enzymes responsible for the steps of this pathway after the γ-glutamyltranspeptidase are not clear. The S to N rearrangements of A to give B and 18 are probably non-enzymatic; in our hands they occurred spontaneously, as did the thiol dimerization of B to 16. Dimerization would certainly be concentration dependent. We cannot say whether the dimers observed in bile samples were true metabolites or artifiacts formed after sample collection. S-Methylation with S-adenosylmethionine requires a thiol methyltransferase, a widely distributed enzyme (Stevens and Bakke, 1990) . Oxidation of thioethers is a common non-enzymatic (Davis et al., 2002) or enzymatic (Davies et al., 1995) reaction.
The N,S-diacyl peptide, 18, and the corresponding 3-derived conjugate, 19, are novel phase 2 metabolites. Compounds 18 and 19 retain the thioester bond, which is expected to be unstable to hydrolysis. That these compounds are biologically and chemically stable and isolable from in vivo samples, can be attributed to their extreme hydrophobicity. The large aromatic groups must exclude water from the vicinity of their thioesters.
This article has not been copyedited and formatted. The final version may differ from this version. Compounds 12-19 were not the only glutathione derived metabolites observed in the metabolism of 1-3. Analogs of 16 and 18 were observed as minor monkey metabolites of 1.
In the same sample of monkey bile, a minor peak was found to have an LC/MS/MS behavior (M-H= 547; rightside ions at 323→259→214) consistent with an oxidized S-methyl, Ncysteinyl acyl derivative of 1. Several other metabolites of 2 seemed to have leftside oxidation and sulfation combined with the acyl S-methyl cys-gly dipeptide as is 12.
Interestingly, these metabolites were found only in bile. Bilary excretion might be expected for metabolites of such high molecular weight (Levine, 1981) and may explain the paucity of literature descriptions of this pathway. The glutathione derived metabolites were not observed in animal or human hepatocyte incubations. Their toxicological implications are unknown. In this study the glutathione derived metabolites were not observed in circulation or in urine so there may not be a large exposure to them. The fact that they are not described in the literature means these pathways are probably not major pathways in any case.
This novel glutathione-based metabolism can lead to a very complex metabolic pattern.
The overall metabolism of 1-3 is summarized in Figure 4 . Preclinical evaluation of the metabolism of carboxylic acid therapeutic agents should include consideration of these glutathione-derived conjugates. We suggest that databases of metabolic pathways should include the 174 and 190 amu transformations among the list of possible metabolites. The dimers are more difficult to add to a single listing of molecular weight ranges. Dimer 16 has a molecular weight of two times the carboxylic acid weight plus 318. Dimer 18 has a molecular weight 2 times the carboxylic acid weight plus 142. We suggest that consideration be given to scanning larger than normal mass ranges when studying the metabolism of carboxylic acids susceptible to the formation of dimeric structures.
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